Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Result For The Year Ending 31.03.2021

 1. AUDITED FINANCIAL RESULT Approval of audited financial results of the Company for the quarter and year ending 31st March 2021. M/s. R. Sathyanarayanan & Co, Chartered Accountant, the Statutory Auditors of the Company have issued Audit Report with modified opinion along with Statement on impact of Modified opinion thereon. Please find enclosed 'Audited Financial Results, Audit Report, 'Statement of Assets & Liabilities' and Statement on Impact of Modified Opinion thereon for the year ended on March 31, 2021. 2. ANNUAL GENERAL MEETING The 26th Annual General Meeting of the members of the Company is scheduled to be held on Saturday the 14th August 2021.
25-06-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Outcome Of Board Meeting

 1. AUDITED FINANCIAL RESULT Approval of audited financial results of the Company for the quarter and year ending 31st March 2021. M/s. R. Sathyanarayanan & Co, Chartered Accountant, the Statutory Auditors of the Company have issued Audit Report with modified opinion along with Statement on impact of Modified opinion thereon. Please find enclosed 'Audited Financial Results, Audit Report, 'Statement of Assets & Liabilities' and Statement on Impact of Modified Opinion thereon for the year ended on March 31, 2021. 2. ANNUAL GENERAL MEETING The 26th Annual General Meeting of the members of the Company is scheduled to be held on Saturday the 14th August 2021.
25-06-2021
Bigul

Annual report for Bafna Pharmaceuticals Ltd. for FY-2021
25-06-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Financial Result And Other Business

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/06/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, 25th June 2021 to inter alia consider and adopt audited financial results for the quarter / year ended 31st March 2021 and any other business with the permission of the Chair.
14-06-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Company Update- United Kingdom (UK)- MHRA Approval For Packaging Lines Ref: Regulation 30 Of The SEBI (LODR) Regulations, 2015

 We would like to update you on the following:- The Company has added two fully automated packaging lines to its existing capacity and they have been approved by the UK-MHRA (Medicines and Healthcare products Regulatory Agency) for the United Kingdom and the European Union (EU). Commenting on the approval, Mr. Mahaveer Chand Bafna, CEO of Bafna Pharmaceuticals Ltd. says, 'The approval from UK- MHRA will provide further momentum to our already expanding business in the UK, Europe and other Regulated Markets.This approval will enable Bafna Pharma to increase its output and consequentially generate higher revenue and profits.
03-05-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Certificate From Practicing Company Secretary For The Half Year Ended 31St March 2021

 Certificate from Practicing Company Secretary under Regulation 40(9) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March 2021 is hereby enclosed for your reference.
27-04-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended March 31, 2021

 Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
20-04-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended March 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Jitendra Kumar PalDesignation :- Company Secretary and Compliance Officer
13-04-2021
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Sub: Compliance Certificate For The Half Year Ended 31St March 2021

 Compliance Certificate that all activities in relation to share transfer facility are maintained by Registrar to an issue and share transfer agent registered with the Board under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March 2021 is hereby enclosed for your reference.
09-04-2021
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Sub.:- Clarification On Price Movement

 We would like to submit that the Company has not made any material announcement having impact on its operation and performance in recent times. The reason for the increase in the price of the shares of the Company is not as a result of any announcement or pending announcement made or to be made by the Company. The Company has not shared any price sensitive information with any market intermediary or any other party and therefore the reason for rise in the price of the shares of the Company is not known to the Company. Discovery of price of security is a function of several factors and is carried out purely-on the Exchange platform. The Company has been sharing and will share all information / announcements that have a bearing on the price / volume behaviour in the scrip with the Stock Exchanges regularly. We have been strictly following all the listing norms for disclosures with the stock exchanges regularly.
18-03-2021
Next Page
Close

Let's Open Free Demat Account